BioCryst Pharmaceuticals Inc (BCRX) Reports Growth in ORLADEYO Revenue and Projects ... [Yahoo! Finance]
BioCryst Pharmaceuticals, Inc. (BCRX)
Last biocryst pharmaceuticals, inc. earnings: 3/5 07:05 am
Check Earnings Report
US:NASDAQ Investor Relations:
biocryst.gcs-web.com/investor-relations
Company Research
Source: Yahoo! Finance
Financial Performance : Q4 net loss narrowed to $61.7 million from $71.5 million in the previous year, with a non-GAAP net loss of $56.4 million. Research and Development : R&D expenses decreased by 4% in Q4 and 14% for the full year, reflecting the discontinuation of certain programs. Operational Efficiency : The company expects operating profit in 2024, with positive EPS and cash flow anticipated in the second half of 2025. 2024 Outlook : BCRX projects ORLADEYO net revenue to be between $380-$400 million, with operating expenses between $365-$375 million. Warning! GuruFocus has detected 3 Warning Signs with BCRX. BioCryst Pharmaceuticals Inc ( NASDAQ:BCRX ) released its 8-K filing on February 26, 2024, detailing its financial results for the fourth quarter and full year of 2023. The company, known for its innovative approach in developing small-molecule drugs targeting infectious and inflammatory diseases, reported a significant increase in revenue, primarily driven by it
Show less
Read more
Impact Snapshot
Event Time:
BCRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCRX alerts
High impacting BioCryst Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
BCRX
News
- With 80% ownership, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) boasts of strong institutional backing [Yahoo! Finance]Yahoo! Finance
- BioCryst to Report First Quarter 2024 Financial Results on May 6GlobeNewswire
- BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory AgencyGlobeNewswire
- Pint Pharma Announces the Approval of ORLADEYO® (berotralstat), the First Oral Therapy Indicated for Preventing Hereditary Angioedema (HAE) Attacks in Adult and Pediatric Patients Aged 12 and Older in Brazil [Yahoo! Finance]Yahoo! Finance
- BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $12.00 price target on the stock.MarketBeat
BCRX
Earnings
- 2/26/24 - Miss
BCRX
Sec Filings
- 4/25/24 - Form ARS
- 4/25/24 - Form DEFA14A
- 4/25/24 - Form DEF
- BCRX's page on the SEC website